Clinical trials: Phase I
Lymphoma, T-Cell, Cutaneous
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.
- Trial name
- NCT00043420
- Testing
- PF-3512676
- Volunteers
- 42 people
- Sponsor
- Pfizer
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00296023
- Testing
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Non-Small-Cell Lung
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
- Trial name
- MAP (NCT07316062)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Malignant Lymphoma
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.
- Trial name
- NCT02131688
- Testing
- Mitoxantrone Hydrochloride Liposome
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Esophageal Cancer
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given in combination with chemotherapy in patients with esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT01102088
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Ascending Single Dose Study
Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants
The primary purpose of this study was to evaluate the single dose safety and pharmacokinetics of TAK-438 in healthy Japanese men.
- Trial name
- NCT02123927
- Testing
- TAK-438
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Takeda
Brain Metastases
Phase 1 Trial for Tumor Treating Field for Drug/Radiation Resistant Brain Metastases
Brain metastasis is a very common disease with poor prognosis, 20% cancer will develop brain metastases(BM), up to 40% by autopsy.
- Trial name
- NCT04967027
- Testing
- ASCLU-300 TTF
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Elevated Low-Density Lipoprotein Cholesterol
Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C.
- Trial name
- NCT05896969
- Testing
- SNK-396 - SAD cohort, SNK-396 - MAD Cohort
- Where
- 3 sites in Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Squamous NSCLC
Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)
This is an open-label, first-in-human, dose escalation study of CV09070101 mRNA (CVHNLC) in patients with metastatic Squamous Non-Small-Cell Lung Cancer (sqNSCLC).
- Trial name
- NCT07073183
- Testing
- CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg
- Where
- 13 sites in United States, France and 1 more
- Sponsor
- CureVac
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer.
- Trial name
- RELY-30 (NCT02917083)
- Testing
- CAR T Cells
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
Advanced Solid Tumor
Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation
This is a phase 1 / 2 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-15293 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2…
- Trial name
- NCT05173805
- Testing
- YL-15293
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Solid Tumor, Adult
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available.
- Trial name
- NCT03355066
- Testing
- SM08502
- Where
- 19 sites in United States
- Volunteers
- 82 people
- Sponsor
- Biosplice Therapeutics, Inc.
Acute Myeloid Leukemia
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy.
- Trial name
- NCT00636922
- Testing
- RAD001(Everolimus)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
Advanced Solid Tumors
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.
- Trial name
- NCT06618651
- Testing
- SHR-3821 injection
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Prostate Cancer
Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy
RATIONALE: Eating a diet rich in isoflavones, compounds found in soy foods, or lycopene, a substance found in tomatoes, may keep prostate cancer from growing.
- Trial name
- NCT00042731
- Testing
- Lycopene, Multivitamin, Soy isoflavones
- Where
- 5 sites in United States
- Volunteers
- 79 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Solid Tumor
A Study of BPI-460372 in Advanced Solid Tumor Patients
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
- Trial name
- NCT05789602
- Testing
- BPI-460372
- Where
- 11 sites in China
- Volunteers
- 82 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Cancer
A Study of LY2801653 in Advanced Cancer
Part A- The purpose of this study is to determine a safe dose of LY2801653 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2801653 in this participant population.
- Trial name
- NCT01285037
- Testing
- LY2801653, Cetuximab, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.